



HAL
open science

Impact of a population-based asthma management program in France (Sophia Asthme): A matched controlled before-and-after quasi-experimental study using the French health insurance database (SNDS)

Fadia Dib, Yann de Rycke, Sylvie Guillo, Alexandre Lafourcade, Chantal Raherison, Camille Taillé, Florence Tubach

► To cite this version:

Fadia Dib, Yann de Rycke, Sylvie Guillo, Alexandre Lafourcade, Chantal Raherison, et al.. Impact of a population-based asthma management program in France (Sophia Asthme): A matched controlled before-and-after quasi-experimental study using the French health insurance database (SNDS). *Pharmacoepidemiology and Drug Safety*, 2019, 28 (8), pp.1097-1108. 10.1002/pds.4842 . hal-02289350

HAL Id: hal-02289350

<https://hal.sorbonne-universite.fr/hal-02289350>

Submitted on 16 Sep 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **TITLE PAGE**

2 **Impact of a population-based asthma management program in France**
3 **(Sophia Asthme): a matched controlled before-and-after quasi experimental**
4 **study using the French health insurance database (SNDS)**

5

6

7 Fadia Dib ^{*1,2,3} MD, Yann de Rycke Y^{*4} MSc, Sylvie Guillo ⁴ MSc, Alexandre Lafourcade ⁴ MSc,
8 Chantal Raheison ^{5,6} MD-PhD, Camille Taillé C ⁷ MD-PhD, Florence Tubach ⁴ MD-PhD.

9

10 *contributed equally

11

12 ¹ AP-HP, Hôpital Bichat-Claude-Bernard, Département d'Epidémiologie, Biostatistiques et
13 Recherche Clinique, F- 75018 Paris, France

14 ² INSERM, CIC-EC 1425, 75018, Paris, France

15 ³ Université Paris Diderot, Sorbonne Paris Cité, ECEVE, UMRS 1123, F-75010 Paris, France

16 ⁴Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique,
17 IPLESP UMR-S1136, CIC 1421, AP-HP, Hôpital Pitié-Salpêtrière, Département Biostatistique
18 Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie, Céphépi, F-
19 75013 Paris, France

20 ⁵ INSERM U1219 team EPICENE, Bordeaux University 146 rue Leo Saignat 33076 Bordeaux
21 France

22 ⁶ Service des Maladies Respiratoires, CHU Bordeaux, Place Amélie Raba Léon, 33000
23 Bordeaux

24 ⁷ Service de Pneumologie et Centre de Compétence des Maladies Pulmonaires Rares, Hôpital
25 Bichat, AP-HP, Paris et Département Hospitalo-Universitaire FIRE, Université Paris Diderot,
26 INSERM UMR 1152, LabEx Inflammex, Paris, France

27

28

29 **Corresponding author:** Pr Florence Tubach, AP-HP, Hôpital Pitié-Salpêtrière, Département
30 Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie,
31 Céphépi, Unité de recherche clinique, INSERM, UMR 1123, CIC-P 1421, F-75013 Paris, France.
32 E-mail: florence.tubach@aphp.fr. Tel: 01.42.16.05.88

33

34 **Key words:** Asthma control, Asthma exacerbation, Asthma outcomes, Disease management
35 program

36

37 **ABSTRACT**

38

39 **Background:** *Sophia Asthme* (SA) is a chronic disease management program of the French
40 national health insurance for adult patients with asthma. We evaluated the early impact of
41 this intervention.

42 **Methods:** We conducted a matched controlled, before-and-after quasi-experimental study
43 within the French Health Insurance Database (SNDS). The SA program was implemented in a
44 set of 18 *Départements* in France and targeted 18-to 44-year-old subjects, with at least two
45 reimbursement dates for asthma drug therapy during the 12-month period prior to program
46 targeting. Change in outcomes was assessed from the “before program” period (January-
47 December 2014) to the “after program implementation” period (Mars 2015–February 2016)
48 in the program group (eligible to SA program in the 18 *Départements*) and in the matched
49 controlled group. The main outcome measure was the before-after change in proportion of
50 subjects with a controllers/(controllers+relievers) ratio >50%.

51 **Findings:** Of the 99,578 subjects of the program group, 9,225 (9.3%) actually participated in
52 SA program. The program had no significant impact on the proportion of subjects with a
53 ratio>50%. However, subjects exposed to SA program were significantly more likely to be
54 dispensed controller medications (OR=1.04; 95% CI, 1.01 to 1.07), and to sustain their use of
55 these medications (OR = 1.08; 95% CI, 1.05 to 1.12).

56 **Interpretation:** We did not demonstrate any significant impact of the program on the
57 primary outcome. The modest yet encouraging findings of this early evaluation suggest the
58 need for reformulation of the program and its evaluation.

59 **Funding:** Caisse Nationale d'Assurance Maladie, Paris, France.

60

61 **INTRODUCTION**

62 Despite the availability of highly effective therapies, achieving asthma control remains
63 tremendously challenging, mostly because of inappropriate use of asthma controller
64 medications.¹ Poor asthma control is responsible for acute exacerbations, which can lead to
65 emergency visits, hospitalizations, and even premature deaths. With an estimated global
66 asthma prevalence among adults ranging from 1% to 21%² and 383,000 related deaths in
67 2015,³ asthma places substantial burdens on the patients, healthcare system and society;^{4,5}
68 it is a major public health problem recognized by the World Health Organization (WHO).³
69 Various programs have been implemented worldwide to improve asthma control.⁶ *Sophia*
70 *Asthme* (SA) program is a chronic disease management program developed by the National
71 French Insurance Service (*Caisse Nationale de l'Assurance Maladie* (CNAM)). It aims to
72 enhance self-management and induce behavior changes, at a sustainable cost to the CNAM
73 budget.
74 *Sophia* program was first developed for diabetic patients in 2008, and included a free web
75 site, written information and telephonic nurse intervention. Recently, a pilot program was
76 developed for asthma patients, aiming at improving asthma control. The objective of this
77 study commissioned by the CNAM was to assess the early effect of the pilot phase of the SA
78 program on asthma outcomes in adult asthma patients.

79

80 **METHODS**

81 **Description of the intervention**

82

83 As a health insurer, the CNAM defines and implements risk-management actions. In this
84 framework, the CNAM launched the pilot experiment of SA program ⁷ in January 2015, in 18
85 among 96 *Départements* of mainland France (*Alpes-Maritimes, Ariège, Côte-d'Or, Haute-*
86 *Garonne, Gers, Gironde, Hérault, Loire, Loiret, Marne, Meurthe-et-Moselle, Nord, Puy-de-*
87 *Dôme, Hautes-Pyrénées, Sarthe, Somme, Tarn, and Seine-Saint-Denis*). Targeting the 18- to
88 44-year-old asthmatic patients, SA program consists primarily of a nurse-delivered, phone-
89 based intervention. Every individual identified in the CNAM claims databases and meeting
90 the selection criteria was invited to take part in the program. The program participants (as
91 opposed to “program non-participants”) started receiving phone calls after mail or online
92 registration made by the patient or their general practitioner (GP).

93 During the first phone call, medical data (asthma control during the last 4 weeks according
94 to Global Initiative for Asthma (GINA) criteria⁸, smoking status and physical exercise practice)
95 were collected. During the following calls, specialized nurses trained in behavioral counseling
96 conducted motivational interviews to promote positive attitudes towards asthma, using a
97 computer-assisted telephone system. Telephone calling periodicity was determined initially
98 and updated afterwards according to a set of criteria reflecting asthma control. After the
99 first phone call, a bimonthly call was planned for patients who had had a hospitalization or
100 ER visit for asthma and for those who had poor symptom control according to GINA criteria.

101 An annual call was planned otherwise. Hospitalization and ER visits for asthma were
102 monitored in real-time (from claims/hospital discharge data) for all program participants, so
103 that patients could benefit from additional calls in the event where asthma hospitalization or

104 ER visit occurred since the last phone call. The same criteria were applied after the second
105 call to determine the periodicity of the subsequent calls. These criteria encompassed both
106 asthma control and medical use from the SNDS database. The content of counseling was
107 recorded in a dedicated software, and tailored for each program participant based on its
108 personal situation (lifestyle, state of health and medical care, social and family
109 environment). Nurses offered appropriate advice and information, in order to promote a
110 greater understanding of the relation between medication adherence and asthma control.
111 They urged patients to seek medical aid and drug treatment, when appropriate.

112 Participants without any telephone call during the intervention period were classified as
113 participants with “low-intensity intervention”, those who had one to three and more than
114 three calls as participants with “moderate-intensity and “high-intensity intervention”,
115 respectively.

116 Besides telephone calls, all program participants received printed material developed by
117 health care professionals and validated by a scientific committee. The material included
118 three leaflets and bi-monthly e-newsletters on asthma. The CNAM also provided
119 unrestricted access to a dedicated website. The written material and the website included
120 information on prevention of exacerbations, smoking cessation, physical activity and
121 management of the disease.

122 **Population**

123 Subjects for the pilot experiment were identified and followed-up within the French Health
124 Insurance database (*Système National Des Données de Santé- SNDS*). Eligibility criteria for
125 the SA program were the following: 1) being aged 18 to 44 years; 2) having at least two
126 different reimbursement dates for asthma medications (R03 codes according to the

127 Anatomical Therapeutic and Chemical (ATC) classification system) in the last 12 months; 3)
128 being covered by the general health insurance scheme; 4) being affiliated with a local
129 healthcare insurance office (*Caisse Primaire d'Assurance Maladie* – CPAM) attached to any
130 of the 18 aforementioned *Départements* for at least 12 months before program deployment;
131 and 5) having a GP also affiliated with a CPAM attached to any of the 18 aforementioned
132 *Départements* for at least 12 months before program deployment.

133 The study population involved all subjects eligible to SA program from *Départements* with
134 the program (i.e., the exposed) matched on a propensity score and stratification variables,
135 with subjects eligible to SA program except they and their GP were affiliated with a CPAM of
136 mainland *Départements* not covered by the program (i.e., the unexposed).

137 The geographical areas chosen for the pilot experiment cover a population of approximately
138 168,000 subjects meeting the aforementioned eligibility criteria. This population was not
139 chosen to be strictly representative of all asthmatic patients in France.

140 **Study design**

141 This evaluation study was designed as a prospective, non-randomized, matched controlled,
142 quasi-experimental before-and-after study.⁹ We defined three periods: (i) 1 January 2014 –
143 31 December 2014: the 12-month “before program implementation” period, (ii) 1 January
144 2015 – 28 February 2015: the implementation period, and (iii) 1 March 2015 – 29 February
145 2016: the 12-month “after program implementation” period. The exposed group
146 (intervention group) was composed of individuals targeted by SA program. The unexposed
147 group was composed of matched individuals meeting eligibility criteria of the intervention
148 group except they and their GP were affiliated with CPAM of mainland *Départements* not
149 covered by the program. Each subject from the intervention group was matched with an

150 unexposed, by stratification variables (asthma-related hospital stay in the last 12 months
151 (yes vs. no), the number of asthma drug deliveries in the last 12 months (2 vs. ≥ 3) and age at
152 program enrollment (< 40 vs. ≥ 40)), and by the propensity score of being exposed.¹⁰⁻¹² We
153 report our findings in accordance with The Reporting Quality of Non Randomized Evaluations
154 of Behavioral and Public Health Interventions (TREND) statement.¹³

155 **Outcome measures**

156 The outcomes were extracted from the SNDS database in 2015 and match the desired
157 effects of the intervention: improved asthma control, improved adherence to controller
158 asthma medications, improved use of healthcare resources, reduced exacerbations and days
159 off work.

160 The primary outcome of interest relied on an asthma medication ratio measuring the
161 proportion of controllers out of total asthma therapy (i.e., controllers and relievers) over a
162 given study period.¹⁴ More precisely, it is the ratio of inhaled corticosteroid (ICS) (whether in
163 fixed combination with long-acting β -agonists (LABAs) or not) plus leukotriene receptor
164 antagonist (LTRA) to total asthma medications (R03 according to ATC classification, Appendix
165 1). In this study, the primary outcome was a high ICS+LTRA/R03 ratio (i.e., $\geq 50\%$), which has
166 been shown in claims data to be associated with fewer asthma-related hospitalizations,
167 fewer emergency room (ER) visits,¹⁴ and better patient-centered asthma outcomes (such as
168 asthma quality of life and symptoms severity).¹⁵ The secondary outcomes included asthma
169 exacerbations (defined as asthma-related hospitalization, asthma –related ER visit or visit to
170 the GP with a dispensation of systemic corticosteroids within seven days of the GP visit),
171 urgent care visits (asthma-related ER room visits and hospitalizations, GP visits for asthma
172 exacerbations), routine asthma visits (GP visits for asthma- defined as dispensation of R03
173 drugs within seven days of the GP visit-, pulmonologist visits, and pulmonary function

174 testing), dispensation of at least one controller medication, dispensation of four or more
175 SABA, sustained use of controller medications (defined as five or more dispensations of ICS -
176 in fixed association with LABA or not- or eight or more units of LTRA), adherence to asthma
177 controller medication (ICS alone or in fixed combination with LABA) as measured by the
178 Medication Refill Adherence (MRA),¹⁶ and work absenteeism as measured by the number of
179 sick leave days related to asthma (Appendix 2).

180 **Data sources**

181 This study was undertaken using a database formed by linking the SNDS¹⁷ database and SA
182 program database, which only included the program participants (questionnaire
183 administered upon entry into the study, and program operational data).

184 In France, the SNDS compiles data from the French National Health Insurance System
185 (including the national hospital-discharge summaries database system - PMSI).¹⁸ Information
186 on healthcare reimbursement, ambulatory and hospital expenditures data, as well as socio-
187 demographics including age, gender, French administrative area of residence, advantage of
188 the Complementary Universal Health Coverage (CMU-C, an individual measure of low socio-
189 economic position (SEP)), and long-term chronic disease status allowing for full medical
190 reimbursement, is available in the SNDS. Data obtained for subjects included in our study
191 comprise sociodemographic and outpatient reimbursed health visits and drugs (coded with
192 ATC classification) on the one hand, and the dates of start and end of hospital stays, with
193 diagnostic codes (primary, related and associated diagnoses coded with the
194 International Information Classification of Diseases, version ICD-10),¹⁹ and most of costly
195 procedures (*Classification commune des actes médicaux*, CCAM),²⁰ on the other hand. The
196 study funder and commissioner (National Health Insurance Fund) undertook the linkage
197 between SNDS records and the information collected within SA program. According to the

198 law (n°2016-41, JORF 2016), a permanent access to SNDS is granted to CNAM employees,
199 but also to subcontractor acting under the authority of CNAM, under very strict conditions
200 (accreditations, secure access...). The statistician authors, as subcontractors to CNAM, had
201 complete and free access to the database. This evaluation is covered by the law of the 6th
202 January 1978 and the decree n ° 2012-1249 of the 9th November 2012 authorizing the
203 creation of personal data processing for the implementation of health prevention and
204 support programs for insured persons. The data processing was the subject of a
205 commitment of conformity to the aforementioned decree.

206 **Power calculation**

207 The a priori power calculation was based on a 5 % increase in the proportion of patients with
208 a ratio ICS+LTRA/R03 \geq 50% among program participants and their matched unexposed
209 subjects in the intervention group. Assuming 160,000 subjects in the exposed group and a
210 rate of 10% of program participation, we reached a power of 80% with a 5% two-tailed test.

211 **Statistical methods**

212 We generated a propensity score with all the subjects, for matching subjects of the
213 intervention (exposed) and unexposed groups within each stratum (caliper=0.20). The
214 probability of being exposed to the program was modeled using a multivariate logistic
215 regression including the following covariates: age, sex, average number of units of the ATC
216 R03 class delivered over the years 2012, 2013 and 2014, CMU-C, prevalence of asthma in the
217 area of residence, as well as characteristics of the geographic location of GP practice (Rey
218 deprivation index,²¹ which is an area-level measure of SEP, the medical density, the size, and
219 the rural or urban character).²² The prevalence of asthma reflects in an integrated and
220 pragmatic way the factors that trigger asthma exacerbations (such as atmospheric

221 conditions, weather conditions, pollination, influenza, etc.); it was derived from a national
222 survey of adults in France (*Enquête santé protection sociale -ESPS*)²³ and a national school
223 health survey.^{24,25} We used standardized mean differences and histograms, for analyzing
224 balance in measured baseline variables before and after matching. After propensity-score
225 matching, we compared differences in patient's outcomes using the difference-in-
226 differences (DiD) analysis approach. We compared the change in outcomes in subjects of the
227 intervention group between the "before program implementation" period and the "after
228 program implementation" period with the change of outcomes in subjects of the unexposed
229 group within the same time period, by use of linear mixed models and generalized mixed
230 models for testing the effect of the program on continuous and dichotomous outcomes,
231 respectively.

232 We conducted subgroup analyses to focus on populations in which the probability to be
233 asthmatic was higher than in the whole study population: (i) patients with at least three
234 different reimbursement dates of R03 in 2013 (*a priori* subgroup analysis), (ii) patients with
235 at least one reimbursement date of R03 in 2012, and (iii) patients with more stringent
236 criteria for the definition of asthma (algorithm developed by the CNAM: subjects with ≥ 1 IgE
237 antagonist or ≥ 1 xanthine or ≥ 1 LTRA (alone or with ICS) or ≥ 3 ICS-LABA or ≥ 3 ICS or ≥ 3
238 LABA or ≥ 3 SABA are considered asthmatic).

239 All analyses were conducted using SAS guide 9.3 (SAS Institute, Cary NC) and R version 3.1.1.
240 R Core Team (2014).²⁶ A level of a two-tailed statistical significance of $p < 0.05$ was used for
241 all statistical tests performed.

242 **RESULTS**

243 **Baseline characteristics**

244 In January 2015, 108,053 subjects were targeted by SA program. Of those, 105,957 were
245 eligible to the intervention group of the study (Figure 1). After matching, 199,156 individuals
246 were included in the study, with 99,578 in each group. The quality of propensity matching is
247 graphically displayed in Supplemental Figures S1A and S1B (Appendix 3). Mean age (\pm SD)
248 was 34 (\pm 7) years (IQR 29-41). Women and CMU-C recipients constituted respectively 60.3%
249 and 19.5% of the study population (Table 1). This population was characterized by features
250 suggesting poor asthma control (less than half of them had an ICS+LTRA/R03 drug ratio \geq 0.5,
251 one third of them exhibited at least one asthma exacerbation during the previous year) and
252 little adherence to treatment (7.1% had a MRA $>$ 80%) (Table 2). A small proportion (11%) of
253 them consulted a lung specialist and about a half received ICS (alone or in combination with
254 LABA) during the year preceding the program.

255 **Description of *Sophia Asthme* program outputs**

256 In the intervention group, 9,225 (9.3%) subjects actually participated in the program. Mean
257 number telephone calls was 1.8. Fifty-four percent of the participants had “low-intensity
258 intervention”; 30.4 % and 15.6 % had “moderate-intensity” and “high-intensity
259 intervention”, respectively.

260 The written support provided was the same for all participants, but only those who
261 communicated their e-mail address (58.8%) received the e-newsletters. Among them, the
262 majority received four or five e-newsletters (18.9 % and 31.8 % of the participants,
263 respectively). The majority of the participants (80.6%) received three leaflets; 16.2 %
264 received two leaflets.

265 **Effects of *Sophia Asthme* program**

266 Table 2 presents the evolution of outcomes before and after program implementation. Most
267 indicators decreased over time in both the intervention and the unexposed group, indicating
268 a period effect. From the “before program implementation” period to the “after program
269 implementation” period, the proportion of subjects with a high ICS+LTRA/R03 decreased in
270 both groups by 4.9 %. No significant difference was observed for other asthma control or for
271 medication adherence indicators. However, the effect of SA program was significant in terms
272 of more frequent patients with at least one controller medication prescription dispensed (OR
273 = 1.04; 95% CI, 1.01 to 1.07), with sustained use of controller medications (OR = 1.08; 95% CI,
274 1.05 to 1.12), and with higher total number of R03 prescriptions dispensed (β = 0.36; 95% CI,
275 0.25 to 0.47) in the intervention group..

276 **Subgroup analyses**

277 The results were similar for patients with three or more R03 prescriptions dispensed in the
278 last 12 months prior to program targeting (in 2013), but the program effect size was
279 relatively larger on the total number of R03 prescriptions dispensed (β = 0.51; 95% CI, 0.35
280 to 0.67). The comparison of program participants to their matched unexposed showed larger
281 effects sizes on the sustained use of controller medications (OR = 1.29; 95% CI, 1.16 to 1.43)
282 and on the total number of R03 prescriptions dispensed (β = 0.76; 95% CI, 0.36 to 1.16). In
283 addition, this subgroup analysis revealed a significant protective effect of the program on
284 the risk of asthma exacerbations (OR = 0.90; 95% CI, 0.83 to 0.99) and a significant decrease
285 in the number of asthma-related sickleave days (β = -0.33; 95% CI, -0.59 to -0.07) (Table 2).
286 Results were similar in the people with asthma according to the CNAM algorithm (Table 3).

287 **DISCUSSION**

288 In this paper, we have examined the early impact of an asthma disease management
289 program in France, SA. The study did not achieve its primary objective, which was to
290 demonstrate an increase in the proportion of patients with a high ICS+LTRA/R03 ratio in the
291 intervention group. Additionally, there was no evidence that the program reduced the risk of
292 asthma-related hospitalizations, ER visits for acute asthma, and asthma exacerbations.
293 However, the program was found to be associated with an increase in the dispensation of
294 R03, the proportion of subjects with dispensation of at least one controller medication, and
295 the sustained use of controller medications. Furthermore, in subgroup analyses focusing on
296 people more likely to be asthmatic, the impact of the program was significant for some
297 asthma treatment-related outcomes (R03 prescriptions dispensed, at least one controller
298 medication prescription dispensed, sustained use of controller medications), and some
299 clinical outcomes (asthma exacerbations, number of asthma-related sickleave days).

300 These results can be interpreted as an absence of impact of the SA program. However,
301 alternative explanations must be discussed. First, the (two months') duration of the
302 implementation period was not sufficiently long to translate into better asthma outcomes.
303 Chronic conditions require long-lasting interventions to promote health behavior changes,
304 such as motivation for medication adherence, smoking cessation, and risk reduction
305 strategies (avoidance of triggers and pollutants). Clinical changes may have occurred outside
306 the timeframe of the observation period. There was an improvement in the use of controller
307 medications (which is a process indicator), we would therefore expect a decrease in asthma
308 exacerbation over a longer time span. Second, the study was underpowered. The initial
309 power calculation was based on the best available data, and suggested that 160 000 patients
310 targeted by the program with a participation rate of 10% would give 80 % power to detect a

311 5 % increase in the primary outcome among SA participants. Unfortunately, the number of
312 individual eligible to the program and the participation rate were smaller than anticipated.
313 The low uptake of the intervention may be due to early assessment (some people may have
314 started to participate after the implementation period). It could also be due to suboptimal
315 targeting of patients diagnosed with asthma: the algorithm used to target the population (at
316 least two deliveries of R03 over the last 12 months) was probably not specific enough,
317 stressing the need for a more specific targeting of the SA program. Third, the population was
318 mainly of low severity asthma, with only 3.7% with LTD status for severe asthma, and 0.36%
319 with an asthma-related hospitalization in 2014. Thus the room for improvement on severe
320 outcomes as hospitalization was very small. Hence, we performed a priori and post-hoc sub-
321 group analysis, so that the captured population better matches the population of interest.
322 These analysis generated results congruent with the primary analysis, but relatively larger
323 and significant positive effects were observed for some of the secondary treatment-related
324 and clinically relevant outcomes (including asthma exacerbations and sickleave days).
325 Fourth, the participation rate to the SA program was low at this early evaluation, inducing a
326 dilution effect. Fifth, we cannot exclude that the program lacked of a component primarily
327 targeting healthcare professionals (*e.g.*, physician education and training). The use of written
328 personalized action-plan for self-management support may also have been missing.
329 According to the literature, even in countries that have been proactive about recommending
330 asthma self-management, three quarters of asthmatic patients are not provided with
331 written action plans.^{27,28} Finally, our findings are consistent with the literature indicating
332 overall small effects and no effect on ER visits.^{6,29}
333 Major strengths of this study include the use of routinely collected health data and the large
334 number of geographical areas involved, allowing a very good external validity of the results;

335 the large sample size, enabling precise effect size estimates; and the relevance of outcomes
336 assessed. In particular, effects on asthma exacerbations and days off work are typically
337 insufficiently reported in studies evaluating asthma management programs, according to the
338 Cochrane systematic review published recently by Peytremann-Bridevaux and colleagues.²⁷
339 Keeping in line with their recommendations, we assessed process of care indicators (*e.g.*,
340 MRA rate for controller medications, dispensation of controller medications) and healthcare
341 utilization indicators (*e.g.*, routine GP visits, ER visits) to better interpret the outcomes
342 results at the patient-level.

343 However, some limitations should be considered when interpreting the results of this study.
344 First, the design of the evaluation was performed after the implementation perimeter was
345 planned by the CNAM means that it was not possible to randomly assign patients to the
346 intervention and control groups nor to promote a more focused target population. We used,
347 as recommended in such cases,³⁰ a controlled before-and-after quasi-experimental design
348 with matching on stratification variables and propensity score. Quasi-experimental studies
349 (where individuals are not randomly allocated)³⁰ include some attempt to limit or control
350 threats to internal validity but we cannot exclude the possibility of a residual confounding
351 bias. Second, in healthcare databases, outcomes are usually addressed by use of proxies,
352 which can induce measurement errors. However, we used proxies similar to those used in
353 other studies, and, by design, these measurement errors are not differential, thus can only
354 bias towards the null. Third, as stated above, the study was underpowered. The *a posteriori*
355 power (keeping the initial assumptions) in the light of observed numbers is of 52% to detect a
356 difference of 5% among the program participants and matched unexposed people (corresponding to
357 a difference of 0.4 % for the whole study population). Here we had a power of 80% to detect in the
358 program participants a difference of 7% (0.6% for the whole study population)

359 **CONCLUSION**

360 In conclusion, SA program piloting phase was not associated with a significant effect at this
361 early phase evaluation on the primary outcome, the ICS+LTRA/R03 ratio. It had a modest
362 impact on some secondary outcomes, particularly on specific subgroups of patients more
363 likely to be asthmatic, leaving open the possibility that suboptimal targeting of the
364 population undermined the evaluation of the program effectiveness.

365 Our results can help the CNAM making informed decisions about whether and how to
366 continue to support this program, by improving the targeting of the population and
367 considering reformulation of the program followed by a subsequent evaluation.

368 **ACKNOWLEDGEMENTS**

369 This study was commissioned and funded by the Caisse Nationale d'Assurance Maladie
370 (CNAM), Paris, France. The CNAM did not have any role in the trial design, data analysis and
371 interpretation, the writing of the manuscript and the decision to submit it for publication.
372 However, they were in charge of data collection (as we used the French claims database and
373 some data from the Sophia Asthme program run by the CNAM).

374

375 **REFERENCES**

- 376 1 Raheison C, Bourdin A, Bonniaud P, *et al.* Updated guidelines (2015) for management
377 and monitoring of adult and adolescent asthmatic patients (from 12 years and older) of
378 the Société de Pneumologie de Langue Française (SPLF) (Full length text). *Rev Mal Respir*
379 2016; **33**: 279–325.
- 380 2 To T, Stanojevic S, Moores G, *et al.* Global asthma prevalence in adults: findings from the
381 cross-sectional world health survey. *BMC Public Health* 2012; **12**: 204.
- 382 3 WHO | Asthma. WHO. <http://www.who.int/mediacentre/factsheets/fs307/en/> (accessed
383 Feb 28, 2018).
- 384 4 Demoly P, Paggiaro P, Plaza V, *et al.* Prevalence of asthma control among adults in France,
385 Germany, Italy, Spain and the UK. *Eur Respir Rev Off J Eur Respir Soc* 2009; **18**: 105–12.
- 386 5 Fuhlbrigge A, Reed ML, Stempel DA, Ortega HO, Fanning K, Stanford RH. The status of
387 asthma control in the U.S. adult population. *Allergy Asthma Proc* 2009; **30**: 529–33.
- 388 6 Peytremann-Bridevaux I, Arditi C, Gex G, Bridevaux P-O, Burnand B. Chronic disease
389 management programmes for adults with asthma. *Cochrane Database Syst Rev* 2015; :
390 CD007988.
- 391 7 sophia, le service d'accompagnement de l'Assurance Maladie | ameli.fr.
392 [https://www.ameli.fr/assure/sante/assurance-maladie/sophia/service-sophia-assurance-](https://www.ameli.fr/assure/sante/assurance-maladie/sophia/service-sophia-assurance-maladie)
393 [maladie](https://www.ameli.fr/assure/sante/assurance-maladie/sophia/service-sophia-assurance-maladie) (accessed Feb 28, 2018).
- 394 8 Bateman ED, Hurd SS, Barnes PJ, *et al.* Global strategy for asthma management and
395 prevention: GINA executive summary. *Eur Respir J* 2008; **31**: 143–78.
- 396 9 13 Including non-randomized studies. [http://handbook-5-](http://handbook-5-1.cochrane.org/chapter_13/13_including_non_randomized_studies.htm)
397 [1.cochrane.org/chapter_13/13_including_non_randomized_studies.htm](http://handbook-5-1.cochrane.org/chapter_13/13_including_non_randomized_studies.htm) (accessed Feb
398 28, 2018).
- 399 10 Rubin DB. Estimating causal effects from large data sets using propensity scores. *Ann*
400 *Intern Med* 1997; **127**: 757–63.
- 401 11 Little RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential
402 outcomes: concepts and analytical approaches. *Annu Rev Public Health* 2000; **21**: 121–45.
- 403 12 Linden A, Adams JL, Roberts N. Using Propensity Scores to Construct Comparable Control
404 Groups for Disease Management Program Evaluation: *Dis Manag Health Outcomes* 2005;
405 **13**: 107–15.
- 406 13 TREND statement | CDC. <https://www.cdc.gov/trendstatement/> (accessed April 17, 2017).
- 407 14 Laforest L, Licaj I, Devouassoux G, Chatte G, Martin J, Ganse EV. Asthma drug ratios and
408 exacerbations: claims data from universal health coverage systems. *Eur Respir J* 2014; **43**:
409 1378–86.

- 410 15Schatz M, Zeiger RS, Vollmer WM, *et al.* The controller-to-total asthma medication ratio is
411 associated with patient-centered as well as utilization outcomes. *Chest* 2006; **130**: 43–50.
- 412 16Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy
413 administrative databases: a proposal for standard definitions and preferred measures.
414 *Ann Pharmacother* 2006; **40**: 1280–8.
- 415 17Palmaro A, Moulis G, Despas F, Dupouy J, Lapeyre-Mestre M. Overview of drug data
416 within French health insurance databases and implications for pharmacoepidemiological
417 studies. *Fundam Clin Pharmacol* 2016; **30**: 616–24.
- 418 18Tuppin P, Rudant J, Constantinou P, *et al.* Value of a national administrative database to
419 guide public decisions: From the système national d’information interrégimes de
420 l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in
421 France. *Rev Epidemiol Sante Publique* 2017; **65 Suppl 4**: S149–67.
- 422 19WHO | International Classification of Diseases. WHO.
423 <http://www.who.int/classifications/icd/en/> (accessed Feb 28, 2018).
- 424 20Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc J-L, Sailer L. French health
425 insurance databases: What interest for medical research? *Rev Med Interne* 2015; **36**: 411–
426 7.
- 427 21Rey G, Jouglu E, Fouillet A, Hémon D. Ecological association between a deprivation index
428 and mortality in France over the period 1997 - 2001: variations with spatial scale, degree
429 of urbanicity, age, gender and cause of death. *BMC Public Health* 2009; **9**: 33.
- 430 22Statistiques | Insee.
431 <https://www.insee.fr/fr/statistiques?debut=0&theme=69&geo=FRANCE-1> (accessed
432 March 1, 2018).
- 433 23Résumé rapport 1820. IRDES. Institut de Recherche en Economie de la santé.
434 <http://www.irdes.fr/EspaceRecherche/BiblioResumeEtSommaire/2011/Rapport1820.htm>
435 (accessed March 1, 2018).
- 436 24Guignon N, Collet M, Gonzalez L. La santé des enfants en grande section de maternelle en
437 2005-2006. Études et Résultats, DREES 2010, n° 737.
- 438 25de Saint Pol Th. Les inégalités géographiques de santé chez les enfants de grande section
439 de maternelle. BE H 2011, n°31.
- 440 26R: The R Project for Statistical Computing. <https://www.r-project.org/> (accessed March 1,
441 2018).
- 442 27Wiener-Ogilvie S, Pinnock H, Huby G, Sheikh A, Partridge MR, Gillies J. Do practices comply
443 with key recommendations of the British Asthma Guideline? If not, why not? *Prim Care
444 Respir J J Gen Pract Airw Group* 2007; **16**: 369–77.

- 445 28 Sulaiman N, Aroni R, Thien F, *et al.* Written Asthma Action Plans (WAAPs) in Melbourne
446 general practices: a sequential mixed methods study. *Prim Care Respir J J Gen Pract Airw*
447 *Group* 2011; **20**: 161–9, 1 p following 169.
- 448 29 Lemmens KMM, Nieboer AP, Huijsman R. A systematic review of integrated use of
449 disease-management interventions in asthma and COPD. *Respir Med* 2009; **103**: 670–91.
- 450 30 anonymous. EPOC-specific resources for review authors | Cochrane Effective Practice and
451 Organisation of Care. <http://epoc.cochrane.org/epoc-specific-resources-review-authors>
452 (accessed March 21, 2016).
- 453

TABLES

Table 1. Characteristics of the included subjects during the “before program” period, across groups: *Sophia Asthma Program* intervention (with program participants and non-participants) and matched unexposed groups.

Variables	Intervention (i.e. exposed) group			P value	Unexposed group	
	Total	Program participants	Program non-participants			
No. of subjects	99,578	9,226	90,353		99,578	
Demographics						
Age (years), mean (SD)	34.40 (7.25)	35.32 (7.18)	34.30 (7.25)	<0.0001	34.22 (7.45)	
Female	60,076 (60.33%)	5,837 (63.27%)	54,240 (60.03%)	<0.0001	60,454 (60.71%)	
CMU-C* recipient	19,366 (19.45%)	1,968 (21.33%)	17,398 (19.26%)	<0.0001	20,819 (20.91%)	
Rey deprivation index (unweighted) quintiles of the municipality where the GP is professionally based				<0.0001		
1 st quintile	26,828 (26.94%)	2,369 (25.68%)	24,459 (27.07%)			24,474 (24.58%)
2 nd quintile	20,107 (20.19%)	1,847 (20.02%)	18,260 (20.21%)			20,102 (20.19%)
3 rd quintile	14,803 (14.87%)	1,310 (14.20%)	13,493 (14.93%)			14,633 (14.70%)
4 th quintile	14,963 (15.03%)	1,408 (15.26%)	13,556 (15.00%)			15,391 (15.46%)
5 th quintile	22,877 (22.97%)	2,292 (24.84%)	20,585 (22.78%)			24,978 (25.08%)
Geographic location of GP Rural (vs Urban)	10,223 (10.27%)	843 (9.14%)	9,380 (10.38%)	0.0002	10,951 (11.00%)	
Clinical						
Long-term chronic disease status for severe asthma in 2014	3,706 (3.72%)	570 (6.18%)	3,136 (3.47%)	<0.0001	6,428 (6.46%)	

(or before)					
Asthma-related hospitalization in 2014	355 (0·36%)	82 (0·89%)	273 (0·30%)	<0·0001	355 (0·36%)
No. of R03 medications					
No. of R03 prescription dispensed during the “before program implementation” period, mean (SD)	4·46 (3·03)	4·87 (3·04)	4·41 (3·02)	<0·0001	6·10 (4·71)
No. of R03 prescriptions dispensed in 2012, mean (SD)	7·74 (6·08)	8·56 (5·94)	7·66 (6·08)	<0·0001	5·39 (5·18)

Data are no. (%) of patients, unless otherwise indicated.

*CMU-C, complementary universal health coverage.

Table 2. Change in outcomes form the “before program implementation” period to the “after program implementation” period: a) for patients in the intervention (i.e. exposed) and unexposed groups, b) for program participants and their matched unexposed

Table 2 a	Intervention (i.e. exposed) group (n=99,578)			Matched Unexposed group (n=99,578)			DiD	OR or slope ^a	P value
	Period “before program”	Period “after program”	Absolute Change	Period “before program”	Period “after program”	Absolute Change			
Process outcomes									
Indicators of asthma control									
ICS+LTRA/R03≥0.5	47,509 (47.71%)	42,588 (42.77%)	-4.9%	48,949 (49.16%)	44,067 (44.25%)	-4.9%	0.0%	1.00 (0.97;1.03)	0.8303
≥ 4 SABA	19,186 (19.27%)	17,887 (17.96%)	-1.3%	27,402 (27.52%)	25,468 (25.58%)	-1.9%	0.6%	1.02 (0.99;1.06)	0.1790
Controller medication									
At least one controller medication dispensed	61,713 (61.97%)	55,730 (55.97%)	-6%	67,383 (67.67%)	60,998 (61.26%)	-6.4%	0.4%	1.04 (1.01;1.07)	0.0082
Sustained use of controller medication ^b	22,674 (22.77%)	21,288 (21.38%)	-1.4%	34,361 (34.51%)	31,614 (31.75%)	-2.8%	1.4%	1.08 (1.05;1.12)	<0.0001
Total no. of R03 dispensed, mean (SD)	5.99 (9.02)	5.67 (9.45)	-0.32	9.87 (14.72)	9.19 (14.79)	-0.68	0.36	0.36 (0.25-0.47)	<0.0001
Adherence to controller asthma medications									
MRA>80%	7,069 (7.10%)	6,958 (6.99%)	-0.1%	14,407 (14.47%)	13,503 (13.56%)	-0.9%	0.8%	1.10 (1.04;1.16)	0.0004

Healthcare utilization outcomes									
Urgent care visits									
At least one asthma-related hospitalization	355 (0·36%)	266 (0·27%)	-0·1%	355 (0·36%)	417 (0·42%)	0·1%	-0·2%	0·54 (0·42;0·69)	<0·0001
At least one ER visit for asthma	3,487 (3·50%)	3,101 (3·11%)	-0·4%	4,723 (4·74%)	4,262 (4·28%)	-0·5%	0·1%	0·99 (0·92;1·06)	0·7084
At least one GP visit for asthma exacerbation ^c	32,731 (32·87%)	30,785 (30·92%)	-2%	31,452 (31·59%)	29,943 (30·07%)	-1·5%	-0·4%	0·98 (0·95;1·01)	0·1423
Routine visits									
At least one pulmonologist visit	11,355 (11·40%)	10,867 (10·91%)	-0·5%	11,785 (11·83%)	10,962 (11·01%)	-0·8%	0·3%	1·04 (1·00;1·08)	0·0774
At least one routine asthma GP visit ^d	59,017 (59·27%)	53,728 (53·96%)	-5·3%	63,153 (63·42%)	57,748 (57·99%)	-5·4%	0·1%	1·01 (0·99;1·04)	0·3642
At least one pulmonary function testing	12,075 (12·13%)	11,241 (11·29%)	-0·8%	12,346 (12·40%)	11,391 (11·44%)	-0·1%	0·1%	1·01 (0·97;1·06)	0·5625
Patient level outcomes									
At least one asthma exacerbation ^e	34,303 (34·45%)	32,247 (32·38%)	-2·1%	33,712 (33·85%)	31,930 (32·07%)	-1·8%	-0·3%	0·98 (0·96-1·02)	0·3530
Work absenteeism									
No. of sickleave days related to asthma, mean number (SD), days	0·87 (9·35)	0·76 (8·43)	-0·11	0·90 (9·96)	0·88 (9·58)	-0·02	0·09	0·09 (-0·20;0·03)	0·1360
At least one sickleave episode related to asthma	4,908 (4·93%)	4,613 (4·63%)	-0·3%	4,909 (4·93%)	4,768 (4·79%)	-0·1%	-0·2%	0·97(0·91;1·02)	0·2299
No. of days of sickleave days related to asthma among those who had one or more days of sickleave days related to asthma, mean (SD) [*]	17,61 (38·46)	16,39 (35·73)	-1·22	18,32 (41·15)	18·43 (39·91)	0·11	-1·33	-	-

Table 2 b	Program participants (n=9,225)			Matched Unexposed group (n=9,225)			DiD	OR or slope ^a	P value
	Period “before program”	Period “after program”	Absolute Change	Period “before program”	Period “after program”	Absolute Change			
Process outcomes									
Indicators of asthma control									
ICS+LTRA/R03≥0.5	5,312 (57.58%)	5,073 (54.99%)	-2.6%	4,748 (51.47%)	4,393 (47.62%)	-3.8%	1.3%	1.06 (0.97;1.17)	0.1871
≥ 4 SABA	2,230 (24.17%)	2,186 (23.70%)	-0.5%	2,743 (29.73%)	2,563 (27.78%)	-2.0%	1.5%	1.10 (0.99;1.20)	0.0861
Controller medication									
At least one controller medication dispensed	6,945 (75.28%)	6,518 (70.66%)	-4.6%	6,630 (71.87%)	6,046 (65.54%)	-6.3%	1.7%	1.09 (0.98; 1.20)	0.1093
Sustained use of controller medication ^b	2,790 (30.24%)	2,799 (30.34%)	0.1%	3,611 (39.14%)	3,267 (35.41%)	-3.7%	3.8%	1.29 (1.16;1.43)	<0.0001
Total no. of R03 dispensed, mean (SD)	7.78 (10.00)	7.84 (11.50)	0.06	10.80 (14.22)	10.10 (15.12)	-0.7	0.76	0.76 (0.36;1.16)	0.0002
Adherence to controller asthma medications									
MRA>80%	896 (9.71%)	947 (10.27%)	0.6%	1,518 (16.46%)	1,455 (15.77%)	-0.7%	1.2%	1.17 (1.01;1.36)	0.0354
Healthcare utilization outcomes									
Urgent care visits									
At least one asthma-related hospitalization, mean (SD)	82 (0.89%)	47 (0.51%)	-0.4%	82 (0.89%)	58 (0.63%)	-0.3%	-0.1%	0.73 (0.40;1.35)	0.3182
At least one ER visit for asthma	513 (5.56%)	420 (4.55%)	-0.1%	507 (5.50%)	435 (4.72%)	-0.8%	-0.2%	0.95 (0.78;1.15)	0.5882

At least one GP visit for asthma exacerbation ^c	3,408 (36.94%)	3,087 (33.46%)	-3.5%	2,942 (31.89%)	2,828 (30.66%)	-1.2%	-2.2%	0.90 (0.82;0.99)	0.0229
Routine visits									
At least one pulmonologist visit	1,685 (18.27%)	2,067 (22.41%)	4.1%	1,181 (12.80%)	1,141 (12.37%)	-0.4%	4.6%	1.41 (1.25;1.59)	<0.0001
At least one routine asthma GP visit ^d	6,551 (71.01%)	6,062 (65.71%)	-5.3%	6,122 (66.36%)	5,626 (60.99%)	-5.4%	0.1%	0.99 (0.90;1.08)	0.7870
At least one pulmonary function testing	1,716 (18.60%)	2,091 (22.67%)	4.1%	1,233 (13.37%)	1,186 (12.86%)	-0.5%	4.6%	1.40 (1.25;1.58)	<0.0001
Patient level outcomes									
At least one asthma exacerbation ^e	3643 (39.49%)	3267 (35.41%)	-4.1%	3193 (34.61%)	3019 (32.73%)	-1.9%	-2.2%	0.90 (0.83;0.99)	0.0289
Work absenteeism									
No. of sickleave days related to asthma, mean number (SD), days	1.21 (10.73)	0.91 (8.78)	-0.30	1.07 (11.31)	1.10 (11.50)	0.03	-0.33	-0.33 (-0.59;-0.07)	0.0119
At least one sickleave episode related to asthma	547 (5.93%)	479 (5.19%)	-0.7%	480 (5.20%)	497 (5.39%)	0.2%	-0.9%	0.83 (0.69;0.99)	0.0463
No. of days of sickleave days related to asthma among those who had one or more days of sickleave days related to asthma, mean (SD) [*]	20.39 (39.39)	17.52 (34.57)	-2.87	20.49 (45.41)	20.41 (45.42)	-0.08	-2.79	-	-

Data are no. (%) of patients, unless otherwise indicated. Values in bold indicate significant associations (p<0.05).

DiD, difference-in-differences (change in outcomes in exposed minus change in outcomes in the unexposed: if the DiD is positive, it means the increase in the variable is higher in the exposed vs unexposed); ER, emergency room; ICS, inhaled corticosteroids; LTRA, leukotriene receptor antagonist; MRA, medication refill adherence; GP, general practitioner; SABA, short-acting β -agonist; LABA, long-acting β -agonist.

^a The following equation was used: $Y_i = \beta_0 + \beta_1 \text{INTERVENTION} + \beta_2 \text{PERIOD} + \beta_3 (\text{INTERVENTION} \times \text{PERIOD}) + e_i$

where Y_i is the value of the dependent variable for the i th patient, INTERVENTION is a dummy variable representing exposition to the program (INTERVENTION=1), PERIOD is a dummy variable (0="before program implementation" period and 1="after program implementation" period). The coefficient of the interaction term (β_3) reflects the impact of the program).

^b Defined as five or more units of ICS/LABA in a single inhaler and/or ICS as a single agent medicine, or 8 or more units of LTRA. This definition was issued from a scoping study provided by the CNAM (data not published).

^c Defined as dispensation of oral or injectable corticosteroids within seven days of the GP visits.

^d Defined as dispensation of R03 drugs within seven days of the GP visits.

^e Defined as hospitalization, ER visits room or a visits to the general practitioner for exacerbation.

* Models were not run as the patients were different.

Table 3. Estimation of SA impact for patients in the intervention and unexposed groups, sub-group analysis.

	Patients with R03 ≥ 3 in the year prior to program implementation			Patients with R03 ≥ 1 in 2012			Patients with asthma as defined by the CNAM algorithm		
	OR or slope	95% CI	P value	OR or slope	95% CI	P value	OR or slope	95% CI	P value
Process outcomes									
Indicators of asthma control									
ICS+LTRA/R03≥0.5	0.98	(0.95 ;1.01)	0.2309	0.98	(0.95;1.02)	0.3347	0.92	(0.88;0.97)	0.0014
≥ 4 SABA	1.04	(1.00;1.08)	0.0630	1.02	(0.99 ;1.06)	0.1880	0.94	(0.90;0.99)	0.0195
Controller medication									
At least one controller medication dispensed	1.08	(1.04;1.13)	0.0002	1.06	(1.03;1.10)	0.0006	0.94	(0.88 ; 1.01)	0.1193
Sustained use of controller medication ^a	1.08	(1.04 ;1.13)	<0.0001	1.07	(1.03;1.11)	0.0009	1.04	(0.99 ; 1.09)	0.1114
Total no. of R03 dispensed, mean (SD)	0.51	(0.35 ;0.67)	<0.0001	0.39	(0.25 ; 0.52)	<0.0001	0.34	(0.09; 0.60)	0.0080
Adherence to controller asthma medications									
MRA>80%	1.09	(1.04;1.15)	0.0007	1.07	(1.02;1.13)	0.0080	1.08	(1.02;1.14)	0.0139
Healthcare utilization outcomes									
Urgent care visits									
At least one asthma-related hospitalization	0.51	(0.39;0.67)	<0.0001	0.50	(0.39;0.65)	<0.0001	0.55	(0.40;0.74)	0.0001
At least one ER visit for asthma	0.97	(0.90;1.04)	0.3588	0.97	(0.91;1.05)	0.4610	0.93	(0.84;1.02)	0.1024

At least one GP visit for asthma exacerbation ^b	0.98	(0.95;1.01)	0.2220	0.98	(0.95;1.01)	0.1652	0.94	(0.90;0.98)	0.0071
Routine visits									
At least one pulmonologist visit	1.01	(0.96;1.06)	0.6157	1.01	(0.96;1.06)	0.7163	0.99	(0.93;1.05)	0.7958
At least one routine asthma GP visit ^c	1.01	(0.98;1.05)	0.4411	1.02	(0.99;1.06)	0.1430	0.89	(0.84;0.94)	<0.0001
At least one pulmonary function testing	0.98	(0.94;1.03)	0.4548	0.98	(0.94;1.03)	0.4490	0.96	(0.90;1.02)	0.1700
Patient level outcomes									
At least one asthma exacerbation ^d	0.99	(0.96;1.02)	0.4722	0.99	(0.96;1.02)	0.3634	0.95	(0.91;0.99)	0.0310
Work absenteeism									
No. of sickleave days related to asthma, mean number (SD), days	-0.14	(-0.29;0.02)	0.0934	-0.14	(-0.28;-0.01)	0.0382	-0.29	(-0.53;-0.05)	0.0197
At least one sickleave episode related to asthma	0.97	(0.90;1.04)	0.3403	0.96	(0.9;1.03)	0.2625	0.92	(0.84;1.00)	0.0534

Data are no. (%) of patients, unless otherwise indicated. Values in bold indicate significant associations (p<0.05).

ER, emergency room; ICS, inhaled corticosteroid; LABA, long-acting β -agonist; LTRA, leukotriene receptor antagonist; SABA, short-acting β -agonists.

^a Defined as five or more units of ICS/LABA in a single inhaler and/or ICS as a single agent medicine, or 8 or more units of LTRA. This definition was issued from a scoping study provided by the CNAM (data not published).

^b Defined as hospitalization, ER visits room or a visits to the general practitioner for exacerbation

FUGURES

Figure 1 : Flow and selection of subjects records for inclusion into propensity analyses ;

